查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654376

癌症診斷市場規模、佔有率、趨勢分析報告，按產品類型、應用、最終用途、測試類型、範圍、地區、細分預測，2025-2030 年

Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Type, By Application, By End-use, By Test Type, By Coverage, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

癌症診斷市場的成長和趨勢

根據Grand View Research, Inc.的新報告，到2030年全球癌症診斷市場規模預計將達到1,550.7億美元。預計 2025 年至 2030 年間，市場複合年成長率為 6.14%。一些組織進行的癌症意識提升計劃數量不斷增加是推動全球診斷產品需求增加的主要因素。國家子宮頸癌聯盟、世界衛生組織、疾病預防控制中心、美國預防服務工作小組等為增加子宮頸癌篩檢而建立的夥伴關係和協作是預計在預測期內推動市場成長的關鍵因素之一。

因此，一些國家正在採取措施，增加篩檢以便早期診斷並支持現有患者。例如，印度政府為治療期間需要幫助的患者推出了「Ayushman Bharat」和總理國家救助基金。同樣，印度政府生物技術部與英國癌症研究中心簽署了一項契約，研究更便宜的診斷和治療方法。

液態生物檢體溶液由於其易於臨床應用，擴大被用作 MCED 測試。近年來，綜合、多種癌症診斷方法已獲得監管部門的核准。該領域的突破性進展和早期檢測的持續研究正在促進市場的成長。此外，循環腫瘤DNA、細胞外囊泡和循環性腫瘤細胞等技術正在為更好的癌症治療鋪平道路。我們的多功能技術可以提供綜合解決方案，以充分發揮液態生物檢體的潛力。

使用伴同性診斷的優點在於可以整體減少製藥和診斷公司所需的時間和成本。開發和商業化一種新分子通常需要10到15年的時間。診斷技術和藥物的共同開發加快了監管核准流程並大大降低了成本。自2016年FDA發布治療和IVD伴同性診斷發展的指引草案以來，許多廠商紛紛鼓勵腫瘤領域伴同性診斷的發展。預計這將對預測期內的市場成長產生積極影響。

癌症診斷市場報告重點

  • 根據產品，消耗品部分將在 2024 年佔據市場的最大佔有率，達到 58.4%，預計在預測期內將以最快的速度成長。
  • 根據類型，體外診斷 (IVD) 部門在 2024 年佔有 52.0% 的佔有率。
  • 由於提高公眾意識的舉措不斷增加以及研發活動的不斷增加，預計乳癌應用領域在預測期內將大幅成長。
  • 根據最終用途，提供高效門診病人服務的實驗室部門佔據市場主導地位。由於住院患者數量的增加，預計未來幾年醫院部門將顯著成長。
  • 由於活體組織切片具有多種益處，包括早期發現疾病，預計切片檢查領域將以顯著的速度成長。
  • 由於核准的新診斷測試數量不斷增加，北美在 2024 年佔據了全球癌症診斷市場的主導地位。
  • 由於普及率的提高和主要參與企業的存在，預計亞太地區在未來幾年將顯著成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素
    • 癌症發生率上升
    • 技術進步
    • 增加公營和私營部門的舉措
    • 廣泛研究和開發新的檢測解決方案
  • 市場限制因素分析
    • 診斷成像成本高昂
    • 輻射暴露可能會限制電腦斷層掃描的使用
    • 再生診斷影像系統的採用日益廣泛
  • 商業環境分析
    • 依因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 波特五力分析
    • COVID-19影響分析
  • 市場機會分析
    • 個人化醫療和伴同性診斷的出現
  • 人工智慧在癌症診斷中的地位
    • 市場趨勢：
    • 新產品開發
    • 主要參與企業及其產品列表
  • 固態和液態生物檢體切片檢查的比較分析
  • 血液診斷的趨勢
  • CfDNA 檢測前景
    • 核准檢查
    • 臨床試驗現狀
  • NGS檢測概況
  • 早期檢測的趨勢
    • 及早發現無症狀患者
    • 有症狀的患者
    • 復發檢測
  • 美國癌症研究津貼狀況
    • 按癌症類型
    • 按狀態
  • 專利申請狀況
  • 對未來科技如何融入病人照護途徑的定性分析

第4章 產品業務分析

  • 癌症診斷市場：產品變異分析
  • 裝置
    • 2018-2030 年裝備市場
    • 基於病理學的儀器
    • 影像設備
    • 其他
  • 耗材
    • 消耗品市場，2018-2030
  • 服務
    • 服務市場，2018-2030

第5章 類型業務分析

  • 癌症診斷市場：類型變異分析
  • 體外診斷
    • 體外診斷市場，2018-2030
    • 2018 年至 2030 年 IVD 市場（按類型）
    • 2018 年至 2030 年 IVD 市場（依技術分類）
  • LDDT
    • LDT 市場，2018-2030
  • 影像學
    • 影像市場，2018 - 2030
    • 磁振造影（MRI）
    • 電腦斷層掃描 (CT)
    • 正子斷層掃描 (PET)
    • 乳房X光檢查
    • 超音波
    • 其他

第6章 應用業務分析

  • 癌症診斷市場：應用趨勢分析
  • 乳癌
    • 乳癌市場，2018-2030
  • 大腸直腸癌
    • 大腸直腸癌市場，2018 - 2030 年
  • 子宮頸癌
    • 子宮頸癌市場，2018 - 2030
  • 肺癌
    • 肺癌市場，2018-2030
  • 攝護腺癌
    • 攝護腺癌市場，2018-2030
  • 皮膚癌
    • 皮膚癌市場，2018-2030
  • 血癌
    • 血液腫瘤市場，2018 - 2030 年
  • 腎癌
    • 腎癌市場，2018-2030
  • 肝癌
    • 肝癌市場，2018 - 2030
  • 胰臟癌
    • 胰臟癌市場，2018 - 2030
  • 卵巢癌
    • 卵巢癌市場，2018 - 2030 年
  • 其他
    • 其他市場，2018-2030

第 7 章 最終用途業務分析

  • 癌症診斷市場：最終用途變異分析
  • 醫院
    • 醫院市場，2018-2030
  • 實驗室
    • 實驗室市場，2018-2030
  • 其他
    • 其他癌症診斷市場，2018 - 2030 年

第 8 章 測試類型業務分析

  • 癌症診斷市場：檢測類型變化分析
  • 切片檢查
    • 2018-2030 年切片檢查市場
    • 細針穿刺
    • 芯切片檢查
    • 手術切片檢查
    • 皮膚切片檢查/穿刺切片檢查
    • 其他
  • 其他
    • 其他癌症診斷市場，2018 - 2030 年

第9章 產品業務分析

  • 癌症診斷市場：產品變異分析
  • 裝置
    • 2018-2030 年裝備市場
  • 耗材套件和試劑
    • 耗材套件和試劑市場，2018-2030
  • 軟體和服務
    • 軟體與服務市場，2018-2030

第10章 業務範圍分析

  • 癌症診斷市場：目標範圍變化分析
  • 公共保險
    • 公共保險市場，2018-2030 年
  • 私人保險
    • 私人保險市場，2018-2030 年

第11章 區域經營分析

  • 2024 年及 2030 年市場佔有率
  • 北美洲
    • 2018 至 2030 年北美癌症診斷市場
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲癌症診斷市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018 至 2030 年亞太地區癌症診斷市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018 至 2030 年拉丁美洲癌症診斷市場
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 2018 年至 2030 年中東和非洲癌症診斷市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第12章 競爭格局

  • 公司分類
  • 2024 年癌症診斷市場佔有率分析
  • 公司簡介
    • Abbott
    • Ge Healthcare
    • F. Hoffmann-la Roche Ltd.
    • Qiagen
    • Bd
    • Siemens Healthcare Gmbh
    • Thermo Fisher Scientific, Inc.
    • Hologic, Inc.
    • Koninklijke Philips Nv（Philips）
    • Illumina, Inc.
    • Agilent Technologies Inc
    • Foundation Medicine
    • Danaher Corporation
    • Bio-rad Laboratories, Inc
    • Perkinelmer Inc
    • Myriad Genetics, Inc.
    • Sysmex Corporation
    • Neogenomics Laboratories, Inc
    • Exact Sciences Corporation
    • Grail
    • Guardant Health Inc,.
    • Tempus
    • Delfi Diagnostics
    • Adela, Inc
    • Clearnote Health
    • Natera
  • 戰略地圖
    • 擴張
    • 獲得
    • 合作
    • 疾病類型/藥物類別發布
    • 夥伴關係
    • 其他
  • 主要公司分銷模式分析
  • 2024 年美國癌症診斷市場競爭熱圖分析
  • 2024 年英國癌症診斷市場競爭熱圖分析
  • 原發診斷不明的癌症公司名單
  • Guardant 檢查評估

第 13 章結論/要點

Product Code: GVR-1-68038-213-6

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is anticipated to reach USD 155.07 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.14% from 2025 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

  • Based on product, the consumables segment held the largest share of 58.4% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period
  • Based on type, in vitro diagnostics (IVD) segment dominated the in 2024 with a share of 52.0% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
  • The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
  • Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
  • The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
  • North America dominated the global cancer diagnostics market in 2024, owing to rise in the number of approvals of new diagnostic tests
  • The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product And Type Snapshot
  • 2.3. Application And End Use Snapshot
  • 2.4. Test Type And Coveragesnapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Prevalence Of Cancer
    • 3.4.2. Technological Advancements
    • 3.4.3. Rising Initiatives Undertaken By Public And Private Organizations
    • 3.4.4. Extensive R&d For The Development Of Novel Testing Solutions
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost Of Diagnostic Imaging
    • 3.5.2. Radiation Exposure Likely To Limit Usage Of Ct Scans
    • 3.5.3. Rising Adoption Of Refurbished Diagnostic Imaging Systems
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis
  • 3.7. Market Opportunity Analysis
    • 3.7.1. Advent Of Personalized Medicine And Companion Diagnostics
  • 3.8. Artificial Intelligence Landscape For Cancer Diagnostics
    • 3.8.1. Market Trends:
    • 3.8.2. New Product Development
    • 3.8.3. List Of Key Players With Their Offerings
  • 3.9. Comparative Analysis Of Solid Vs. Liquid Biopsies
  • 3.10. Trends In Blood-based Diagnostics
  • 3.11. Cfdna Test Landscape
    • 3.11.1. Approved Tests
    • 3.11.2. Clinical Trials Landscape
  • 3.12. Ngs Tests Landscape
  • 3.13. Trends In Early Detection
    • 3.13.1. Early Detection In Asymptomatic Patients
    • 3.13.2. Symptomatic Patients
    • 3.13.3. Recurrence Detection
  • 3.14. U.S. Cancer Research Grants Funding Landscape
    • 3.14.1. By Cancer Type
    • 3.14.2. By State
  • 3.15. Patent Filing Landscape
  • 3.16. Qualitative Analysis Of How Upcoming Technologies Fit Into Patient Pathways

Chapter 4. Product Business Analysis

  • 4.1. Cancer Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2. Pathology Based-instruments
      • 4.2.2.1. Slide Staining Systems
        • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.2. Tissue Processing Systems
        • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.3. Cell Processors
        • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.4. Pcr Instruments
        • 4.2.2.4.1. Pcr Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.5. Ngs Instruments
        • 4.2.2.5.1. Ngs Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.6. Microarrays
        • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 4.2.2.7. Other Pathology-based Instruments
        • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.3. Imaging Instruments
    • 4.2.4. Others
  • 4.3. Consumables
    • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
  • 4.4. Services
    • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

  • 5.1. Cancer Diagnostics Market: Type Movement Analysis
  • 5.2. IVD
    • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
    • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
      • 5.2.2.1. Diagnosis
        • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
      • 5.2.2.2. Early Detection
        • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.3. Therapy Selection
        • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.4. Monitoring
        • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
    • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
      • 5.2.3.1. Polymerase Chain Reaction (Pcr)
        • 5.2.3.1.1. Polymerase Chain Reaction (Pcr) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.2. In Situ Hybridization (Ish)
        • 5.2.3.2.1. In Situ Hybridization (Ish) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.3. Immunohistochemistry (Ihc)
        • 5.2.3.3.1. Immunohistochemistry (Ihc) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.4. Next-generation Sequencing (Ngs)
        • 5.2.3.4.1. Next-generation Sequencing (Ngs) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.5. Microarrays
        • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.6. Flow Cytometry
        • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
      • 5.2.3.7. Immunoassays
        • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.8. Other IVD Testing Technologies
        • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
  • 5.3. LDT
    • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
  • 5.4. Imaging
    • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
    • 5.4.2. Magnetic Resonance Imaging (Mri)
      • 5.4.2.1. Magnetic Resonance Imaging (Mri) Market, 2018 - 2030 (USD Billion)
    • 5.4.3. Computed Tomography (Ct)
      • 5.4.3.1. Computed Tomography (Ct) Market, 2018 - 2030 (USD Billion)
    • 5.4.4. Positron Emission Tomography (Pet)
      • 5.4.4.1. Positron Emission Tomography (Pet) Market, 2018 - 2030 (USD Billion)
    • 5.4.5. Mammography
      • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
    • 5.4.6. Ultrasound
      • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

  • 6.1. Cancer Diagnostics Market: Application Movement Analysis
  • 6.2. Breast Cancer
    • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
  • 6.3. Colorectal Cancer
    • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
  • 6.4. Cervical Cancer
    • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
  • 6.5. Lung Cancer
    • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
  • 6.6. Prostate Cancer
    • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
  • 6.7. Skin Cancer
    • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
  • 6.8. Blood Cancer
    • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
  • 6.9. Kidney Cancer
    • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
  • 6.10. Liver Cancer
    • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
  • 6.11. Pancreatic Cancer
    • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
  • 6.12. Ovarian Cancer
    • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
  • 6.13. Others
    • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End Use Business Analysis

  • 7.1. Cancer Diagnostics Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 7.3. Laboratories
    • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
  • 7.4. Others
    • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

  • 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
  • 8.2. Biopsy
    • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.2. Fine-needle Aspiration
      • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Core Biopsy
      • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.4. Surgical Biopsy
      • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.5. Skin Biopsy /punch Biopsy
      • 8.2.5.1. Skin Biopsy /punch Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.6. Others
      • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
  • 8.3. Others
    • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

  • 9.1. Cancer Diagnostics Market: Product Movement Analysis
  • 9.2. Instruments
    • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 9.3. Consumables Kits And Reagents
    • 9.3.1. Consumables Kits And Reagents Market, 2018 - 2030 (USD Billion)
  • 9.4. Software And Services
    • 9.4.1. Software And Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Coverage Business Analysis

  • 10.1. Cancer Diagnostics Market: Coverage Movement Analysis
  • 10.2. Public Insurance
    • 10.2.1. Public Insurance Market, 2018 - 2030 (USD Billion)
  • 10.3. Private Insurance
    • 10.3.1. Private Insurance Market, 2018 - 2030 (USD Billion)

Chapter 11. Regional Business Analysis

  • 11.1. Cancer Diagnostics Market Share By Region, 2024 & 2030
  • 11.2. North America
    • 11.2.1. North America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.2.2. U.S.
      • 11.2.2.1. Key Country Dynamics
      • 11.2.2.2. Target Disease Prevalence
      • 11.2.2.3. Competitive Scenario
      • 11.2.2.4. Regulatory Framework
      • 11.2.2.5. Reimbursement Scenario
      • 11.2.2.6. U.S. Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.2.3. Canada
      • 11.2.3.1. Key Country Dynamics
      • 11.2.3.2. Target Disease Prevalence
      • 11.2.3.3. Competitive Scenario
      • 11.2.3.4. Regulatory Framework
      • 11.2.3.5. Reimbursement Scenario
      • 11.2.3.6. Canada Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3. Europe
    • 11.3.1. Europe Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.2. Germany
      • 11.3.2.1. Key Country Dynamics
      • 11.3.2.2. Target Disease Prevalence
      • 11.3.2.3. Competitive Scenario
      • 11.3.2.4. Regulatory Framework
      • 11.3.2.5. Reimbursement Scenario
      • 11.3.2.6. Germany Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.3. Uk
      • 11.3.3.1. Key Country Dynamics
      • 11.3.3.2. Target Disease Prevalence
      • 11.3.3.3. Competitive Scenario
      • 11.3.3.4. Regulatory Framework
      • 11.3.3.5. Reimbursement Scenario
      • 11.3.3.6. Uk Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.4. France
      • 11.3.4.1. Key Country Dynamics
      • 11.3.4.2. Target Disease Prevalence
      • 11.3.4.3. Competitive Scenario
      • 11.3.4.4. Regulatory Framework
      • 11.3.4.5. Reimbursement Scenario
      • 11.3.4.6. France Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.5. Italy
      • 11.3.5.1. Key Country Dynamics
      • 11.3.5.2. Target Disease Prevalence
      • 11.3.5.3. Competitive Scenario
      • 11.3.5.4. Regulatory Framework
      • 11.3.5.5. Reimbursement Scenario
      • 11.3.5.6. Italy Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.6. Spain
      • 11.3.6.1. Key Country Dynamics
      • 11.3.6.2. Target Disease Prevalence
      • 11.3.6.3. Competitive Scenario
      • 11.3.6.4. Regulatory Framework
      • 11.3.6.5. Reimbursement Scenario
      • 11.3.6.6. Spain Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.7. Denmark
      • 11.3.7.1. Key Country Dynamics
      • 11.3.7.2. Target Disease Prevalence
      • 11.3.7.3. Competitive Scenario
      • 11.3.7.4. Regulatory Framework
      • 11.3.7.5. Reimbursement Scenario
      • 11.3.7.6. Denmark Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.8. Sweden
      • 11.3.8.1. Key Country Dynamics
      • 11.3.8.2. Target Disease Prevalence
      • 11.3.8.3. Competitive Scenario
      • 11.3.8.4. Regulatory Framework
      • 11.3.8.5. Reimbursement Scenario
      • 11.3.8.6. Sweden Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.9. Norway
      • 11.3.9.1. Key Country Dynamics
      • 11.3.9.2. Target Disease Prevalence
      • 11.3.9.3. Competitive Scenario
      • 11.3.9.4. Regulatory Framework
      • 11.3.9.5. Reimbursement Scenario
      • 11.3.9.6. Norway Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4. Asia Pacific
    • 11.4.1. Asia Pacific Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.2. Japan
      • 11.4.2.1. Key Country Dynamics
      • 11.4.2.2. Target Disease Prevalence
      • 11.4.2.3. Competitive Scenario
      • 11.4.2.4. Regulatory Framework
      • 11.4.2.5. Reimbursement Scenario
      • 11.4.2.6. Japan Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.3. China
      • 11.4.3.1. Key Country Dynamics
      • 11.4.3.2. Target Disease Prevalence
      • 11.4.3.3. Competitive Scenario
      • 11.4.3.4. Regulatory Framework
      • 11.4.3.5. Reimbursement Scenario
      • 11.4.3.6. China Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.4. India
      • 11.4.4.1. Key Country Dynamics
      • 11.4.4.2. Target Disease Prevalence
      • 11.4.4.3. Competitive Scenario
      • 11.4.4.4. Regulatory Framework
      • 11.4.4.5. Reimbursement Scenario
      • 11.4.4.6. India Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.5. South Korea
      • 11.4.5.1. Key Country Dynamics
      • 11.4.5.2. Target Disease Prevalence
      • 11.4.5.3. Competitive Scenario
      • 11.4.5.4. Regulatory Framework
      • 11.4.5.5. Reimbursement Scenario
      • 11.4.5.6. South Korea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.6. Australia
      • 11.4.6.1. Key Country Dynamics
      • 11.4.6.2. Target Disease Prevalence
      • 11.4.6.3. Competitive Scenario
      • 11.4.6.4. Regulatory Framework
      • 11.4.6.5. Reimbursement Scenario
      • 11.4.6.6. Australia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.7. Thailand
      • 11.4.7.1. Key Country Dynamics
      • 11.4.7.2. Target Disease Prevalence
      • 11.4.7.3. Competitive Scenario
      • 11.4.7.4. Regulatory Framework
      • 11.4.7.5. Reimbursement Scenario
      • 11.4.7.6. Thailand Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5. Latin America
    • 11.5.1. Latin America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.2. Brazil
      • 11.5.2.1. Key Country Dynamics
      • 11.5.2.2. Target Disease Prevalence
      • 11.5.2.3. Competitive Scenario
      • 11.5.2.4. Regulatory Framework
      • 11.5.2.5. Reimbursement Scenario
      • 11.5.2.6. Brazil Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.3. Mexico
      • 11.5.3.1. Key Country Dynamics
      • 11.5.3.2. Target Disease Prevalence
      • 11.5.3.3. Competitive Scenario
      • 11.5.3.4. Regulatory Framework
      • 11.5.3.5. Reimbursement Scenario
      • 11.5.3.6. Mexico Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.4. Argentina
      • 11.5.4.1. Key Country Dynamics
      • 11.5.4.2. Target Disease Prevalence
      • 11.5.4.3. Competitive Scenario
      • 11.5.4.4. Regulatory Framework
      • 11.5.4.5. Reimbursement Scenario
      • 11.5.4.6. Argentina Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6. Mea
    • 11.6.1. Mea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.2. South Africa
      • 11.6.2.1. Key Country Dynamics
      • 11.6.2.2. Target Disease Prevalence
      • 11.6.2.3. Competitive Scenario
      • 11.6.2.4. Regulatory Framework
      • 11.6.2.5. Reimbursement Scenario
      • 11.6.2.6. South Africa Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.3. Saudi Arabia
      • 11.6.3.1. Key Country Dynamics
      • 11.6.3.2. Target Disease Prevalence
      • 11.6.3.3. Competitive Scenario
      • 11.6.3.4. Regulatory Framework
      • 11.6.3.5. Reimbursement Scenario
      • 11.6.3.6. Saudi Arabia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.4. Uae
      • 11.6.4.1. Key Country Dynamics
      • 11.6.4.2. Target Disease Prevalence
      • 11.6.4.3. Competitive Scenario
      • 11.6.4.4. Regulatory Framework
      • 11.6.4.5. Reimbursement Scenario
      • 11.6.4.6. Uae Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.5. Kuwait
      • 11.6.5.1. Key Country Dynamics
      • 11.6.5.2. Target Disease Prevalence
      • 11.6.5.3. Competitive Scenario
      • 11.6.5.4. Regulatory Framework
      • 11.6.5.5. Reimbursement Scenario
      • 11.6.5.6. Kuwait Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

  • 12.1. Company Categorization
  • 12.2. Cancer Diagnostics Market Share Analysis, 2024
  • 12.3. Company Profiles
    • 12.3.1. Abbott
      • 12.3.1.1. Company Overview
      • 12.3.1.2. Financial Performance
      • 12.3.1.3. Product Benchmarking
      • 12.3.1.4. Strategic Initiatives
    • 12.3.2. Ge Healthcare
      • 12.3.2.1. Company Overview
      • 12.3.2.2. Financial Performance
      • 12.3.2.3. Product Benchmarking
      • 12.3.2.4. Strategic Initiatives
    • 12.3.3. F. Hoffmann-la Roche Ltd.
      • 12.3.3.1. Company Overview
      • 12.3.3.2. Financial Performance
      • 12.3.3.3. Product Benchmarking
      • 12.3.3.4. Strategic Initiatives
    • 12.3.4. Qiagen
      • 12.3.4.1. Company Overview
      • 12.3.4.2. Financial Performance
      • 12.3.4.3. Product Benchmarking
      • 12.3.4.4. Strategic Initiatives
    • 12.3.5. Bd
      • 12.3.5.1. Company Overview
      • 12.3.5.2. Financial Performance
      • 12.3.5.3. Product Benchmarking
      • 12.3.5.4. Strategic Initiatives
    • 12.3.6. Siemens Healthcare Gmbh
      • 12.3.6.1. Company Overview
      • 12.3.6.2. Financial Performance
      • 12.3.6.3. Product Benchmarking
      • 12.3.6.4. Strategic Initiatives
    • 12.3.7. Thermo Fisher Scientific, Inc.
      • 12.3.7.1. Company Overview
      • 12.3.7.2. Financial Performance
      • 12.3.7.3. Product Benchmarking
      • 12.3.7.4. Strategic Initiatives
    • 12.3.8. Hologic, Inc.
      • 12.3.8.1. Company Overview
      • 12.3.8.2. Financial Performance
      • 12.3.8.3. Product Benchmarking
      • 12.3.8.4. Strategic Initiatives
    • 12.3.9. Koninklijke Philips N.v. (Philips)
      • 12.3.9.1. Company Overview
      • 12.3.9.2. Financial Performance
      • 12.3.9.3. Product Benchmarking
      • 12.3.9.4. Strategic Initiatives
    • 12.3.10. Illumina, Inc.
      • 12.3.10.1. Company Overview
      • 12.3.10.2. Financial Performance
      • 12.3.10.3. Product Benchmarking
      • 12.3.10.4. Strategic Initiatives
    • 12.3.11. Agilent Technologies Inc
      • 12.3.11.1. Company Overview
      • 12.3.11.2. Financial Performance
      • 12.3.11.3. Product Benchmarking
      • 12.3.11.4. Strategic Initiatives
    • 12.3.12. Foundation Medicine
      • 12.3.12.1. Company Overview
      • 12.3.12.2. Financial Performance
      • 12.3.12.3. Product Benchmarking
      • 12.3.12.4. Strategic Initiatives
    • 12.3.13. Danaher Corporation
      • 12.3.13.1. Company Overview
      • 12.3.13.2. Financial Performance
      • 12.3.13.3. Product Benchmarking
      • 12.3.13.4. Strategic Initiatives
    • 12.3.14. Bio-rad Laboratories, Inc
      • 12.3.14.1. Company Overview
      • 12.3.14.2. Financial Performance
      • 12.3.14.3. Product Benchmarking
      • 12.3.14.4. Strategic Initiatives
    • 12.3.15. Perkinelmer Inc
      • 12.3.15.1. Company Overview
      • 12.3.15.2. Financial Performance
      • 12.3.15.3. Product Benchmarking
      • 12.3.15.4. Strategic Initiatives
    • 12.3.16. Myriad Genetics, Inc.
      • 12.3.16.1. Company Overview
      • 12.3.16.2. Financial Performance
      • 12.3.16.3. Product Benchmarking
      • 12.3.16.4. Strategic Initiatives
    • 12.3.17. Sysmex Corporation
      • 12.3.17.1. Company Overview
      • 12.3.17.2. Financial Performance
      • 12.3.17.3. Product Benchmarking
      • 12.3.17.4. Strategic Initiatives
    • 12.3.18. Neogenomics Laboratories, Inc
      • 12.3.18.1. Company Overview
      • 12.3.18.2. Financial Performance
      • 12.3.18.3. Product Benchmarking
      • 12.3.18.4. Strategic Initiatives
    • 12.3.19. Exact Sciences Corporation
      • 12.3.19.1. Company Overview
      • 12.3.19.2. Financial Performance
      • 12.3.19.3. Product Benchmarking
      • 12.3.19.4. Strategic Initiatives
    • 12.3.20. Grail
      • 12.3.20.1. Company Overview
      • 12.3.20.2. Financial Performance
      • 12.3.20.3. Product Benchmarking
      • 12.3.20.4. Strategic Initiatives
    • 12.3.21. Guardant Health Inc,.
      • 12.3.21.1. Company Overview
      • 12.3.21.2. Financial Performance
      • 12.3.21.3. Product Benchmarking
      • 12.3.21.4. Strategic Initiatives
    • 12.3.22. Tempus
      • 12.3.22.1. Company Overview
      • 12.3.22.2. Financial Performance
      • 12.3.22.3. Product Benchmarking
      • 12.3.22.4. Strategic Initiatives
    • 12.3.23. Delfi Diagnostics
      • 12.3.23.1. Company Overview
      • 12.3.23.2. Financial Performance
      • 12.3.23.3. Product Benchmarking
      • 12.3.23.4. Strategic Initiatives
    • 12.3.24. Adela, Inc
      • 12.3.24.1. Company Overview
      • 12.3.24.2. Financial Performance
      • 12.3.24.3. Product Benchmarking
      • 12.3.24.4. Strategic Initiatives
    • 12.3.25. Clearnote Health
      • 12.3.25.1. Company Overview
      • 12.3.25.2. Financial Performance
      • 12.3.25.3. Product Benchmarking
      • 12.3.25.4. Strategic Initiatives
    • 12.3.26. Natera
      • 12.3.26.1. Company Overview
      • 12.3.26.2. Financial Performance
      • 12.3.26.3. Product Benchmarking
      • 12.3.26.4. Strategic Initiatives
  • 12.4. Strategy Mapping
    • 12.4.1. Expansion
    • 12.4.2. Acquisition
    • 12.4.3. Collaborations
    • 12.4.4. Disease Type/drug Class Launch
    • 12.4.5. Partnerships
    • 12.4.6. Others
  • 12.5. Distribution Model Analysis For Major Players
  • 12.6. Competitive Heat Map Analysis For U.S. Cancer Diagnostics Market, 2024
  • 12.7. Competitive Heat Map Analysis For Uk Cancer Diagnostics Market, 2024
  • 12.8. List Of Cancers Of Unknown Primary Diagnostics Companies
  • 12.9. Guardant Test Evaluation

Chapter 13. Conclusion/key Takeways

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global cancer diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 5 Global cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 6 Global cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Global cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 8 North America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 9 North America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 10 North America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 11 North America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 12 North America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 13 North America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 14 North America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 15 U.S. cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 16 U.S. cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 17 U.S. cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 18 U.S. cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 19 U.S. cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 20 U.S. cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 21 Canada cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 22 Canada cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 23 Canada cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Canada cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Canada cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 26 Canada cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 27 Europe cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 28 Europe cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Europe cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 30 Europe cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 31 Europe cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 32 Europe cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 33 Europe cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 34 UK cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 35 UK cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 36 UK cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 37 UK cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 UK cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 39 UK cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 40 Germany cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 41 Germany cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 42 Germany cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 43 Germany cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Germany cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 45 Germany cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 46 France cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 47 France cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 48 France cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 49 France cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 50 France cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 51 France cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 52 Italy cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 53 Italy cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Italy cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 55 Italy cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 Italy cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 57 Italy cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 58 Spain cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 59 Spain cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 60 Spain cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 61 Spain cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Spain cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 63 Spain cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 64 Denmark cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 65 Denmark cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Denmark cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 67 Denmark cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 68 Denmark cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 69 Denmark cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 70 Sweden cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 71 Sweden cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 72 Sweden cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 73 Sweden cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 74 Sweden cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 75 Sweden cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 76 Norway cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 Norway cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 78 Norway cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 79 Norway cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 80 Norway cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 81 Norway cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 82 Asia Pacific cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 83 Asia Pacific cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 84 Asia Pacific cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 85 Asia Pacific cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 86 Asia Pacific cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 87 Asia Pacific cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 88 Asia Pacific cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 89 Japan cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 90 Japan cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 91 Japan cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 92 Japan cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 93 Japan cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 94 Japan cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 95 China cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 96 China cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 97 China cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 98 China cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 99 China cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 100 China cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 101 India cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 102 India cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 103 India cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 104 India cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 105 India cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 106 India cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 107 South Korea cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 108 South Korea cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 109 South Korea cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 110 South Korea cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 111 South Korea cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 112 South Korea cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 113 Thailand cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 114 Thailand cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 115 Thailand cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 116 Thailand cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 117 Thailand cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 118 Thailand cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 119 Australia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 120 Australia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 121 Australia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 122 Australia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 123 Australia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 124 Australia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 125 Latin America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 126 Latin America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 127 Latin America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 128 Latin America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 129 Latin America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 130 Latin America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 131 Latin America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 132 Brazil cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 133 Brazil cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 134 Brazil cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 135 Brazil cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 136 Brazil cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 137 Brazil cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 138 Mexico cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 139 Mexico cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 140 Mexico cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 141 Mexico cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 142 Mexico cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 143 Mexico cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 144 Argentina cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 145 Argentina cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 146 Argentina cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 147 Argentina cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 148 Argentina cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 149 Argentina cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 150 Middle East & Africa cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 151 Middle East & Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 152 Middle East & Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 153 Middle East & Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 154 Middle East & Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 155 Middle East & Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 156 Middle East & Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 157 South Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 158 South Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 159 South Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 160 South Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 161 South Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 162 South Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 163 Saudi Arabia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 164 Saudi Arabia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 165 Saudi Arabia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 166 Saudi Arabia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 167 Saudi Arabia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 168 Saudi Arabia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 169 UAE cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 170 UAE cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 171 UAE cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 172 UAE cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 173 UAE cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 174 UAE cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 175 Kuwait cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 176 Kuwait cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 177 Kuwait cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 178 Kuwait cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 179 Kuwait cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 180 Kuwait cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and type segment snapshot
  • Fig. 11 Application segment snapshot
  • Fig. 12 End use and test type segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Cancer diagnostics market value, 2024 (USD Billion)
  • Fig. 15 Market dynamics
  • Fig. 16 Incidence of most common cancers globally, 2024
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 Cancer diagnostics market: Product outlook and key takeaways
  • Fig. 20 Cancer diagnostics market: Product movement analysis
  • Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Slide staining systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 24 Tissue processing systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 25 Cell processors market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 PCR instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 NGS instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Other pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Imaging instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Consumables market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Kits & reagents market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 35 Probes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Services market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Cancer diagnostics market: Type outlook and key takeaways
  • Fig. 39 Cancer diagnostics market: Type movement analysis
  • Fig. 40 IVD market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Diagnosis market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Early detection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Therapy selection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Monitoring market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 45 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 46 In Situ Hybridization (ISH) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Immunohistochemistry (IHC) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Next-generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 50 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 51 Immunoassays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Other IVD testing technologies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 LDT market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 54 Imaging market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Magnetic Resonance Imaging (MRI) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 Computed Tomography (CT) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Positron Emission Tomography (PET) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 58 Mammography market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 Ultrasound market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Cancer diagnostics market: Application outlook and key takeaways
  • Fig. 62 Cancer diagnostics market: Application movement analysis
  • Fig. 63 Breast cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 64 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Lung cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 68 Skin cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Blood cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 70 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Liver cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 72 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 74 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Cancer diagnostics market: End use outlook and key takeaways
  • Fig. 76 Cancer diagnostics market: End use movement analysis
  • Fig. 77 Hospitals market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 78 Laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 80 Cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 81 Cancer diagnostics market: Test type movement analysis
  • Fig. 82 Biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Fine-needle aspiration market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 84 Core biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 Surgical biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 86 Skin biopsy/punch biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 88 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Cancer diagnostics market: Coverage outlook and key takeaways
  • Fig. 90 Cancer diagnostics market: Coverage movement analysis
  • Fig. 91 Public insurance market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 92 Private insurance market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Cancer Diagnostics Market revenue, by region, 2024 & 2030 (USD Billion)
  • Fig. 94 Regional marketplace: Key takeaways
  • Fig. 95 Regional marketplace: Key takeaways
  • Fig. 96 North America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 97 Key country dynamics
  • Fig. 98 U.S. cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 99 Cancer incidence, 2018 - 2030
  • Fig. 100 Ways to obtain coverage
  • Fig. 101 Key country dynamics
  • Fig. 102 Canada cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Cancer incidence, 2018 - 2030
  • Fig. 104 Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 105 Key country dynamics
  • Fig. 106 UK cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 107 Cancer incidence, 2018 - 2030
  • Fig. 108 Key country dynamics
  • Fig. 109 Germany cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 110 Cancer incidence, 2018 - 2030
  • Fig. 111 Key country dynamics
  • Fig. 112 France cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 113 Cancer incidence, 2018 - 2030
  • Fig. 114 Key country dynamics
  • Fig. 115 Spain cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 116 Cancer incidence, 2018 - 2030
  • Fig. 117 Key country dynamics
  • Fig. 118 Italy cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 119 Cancer incidence, 2018 - 2030
  • Fig. 120 Key country dynamics
  • Fig. 121 Denmark cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 122 Target disease prevalence
  • Fig. 123 Key country dynamics
  • Fig. 124 Sweden cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 125 Five most common cancers in Sweden
  • Fig. 126 Key country dynamics
  • Fig. 127 Norway cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 128 Number of new cancer cases in 2020, both sexes, all ages
  • Fig. 129 Rest of Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 130 Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 Key country dynamics
  • Fig. 132 Japan cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Cancer incidence, 2018 to 2030
  • Fig. 134 Key country dynamics
  • Fig. 135 China cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 136 Cancer incidence, 2018 to 2030
  • Fig. 137 China regulatory details
  • Fig. 138 Key country dynamics
  • Fig. 139 India cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 140 Cancer incidence, 2018 to 2030
  • Fig. 141 Key country dynamics
  • Fig. 142 Australia cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 143 Cancer incidence, 2018 to 2030
  • Fig. 144 Key country dynamics
  • Fig. 145 Thailand cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 146 Cancer incidence, 2020 to 2030
  • Fig. 147 Key country dynamics
  • Fig. 148 South Korea cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 149 Cancer incidence 2018 to 2030
  • Fig. 150 South Korean regulations in four hierarchical orders
  • Fig. 151 South Korea reimbursement scenario
  • Fig. 152 Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 153 Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 154 Key country dynamics
  • Fig. 155 Brazil cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 156 Estimated number of new cancer cases in Brazil
  • Fig. 157 Key country dynamics
  • Fig. 158 Mexico cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 159 Estimated number of new cancer cases in Mexico
  • Fig. 160 Key country dynamics
  • Fig. 161 Argentina cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 162 Estimated number of new cancer cases in Argentina
  • Fig. 163 Rest of Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 164 MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 165 Key country dynamics
  • Fig. 166 South Africa cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 167 Cancer prevalence-2018 - 2030
  • Fig. 168 Key country dynamics
  • Fig. 169 Saudi Arabia cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 170 Cancer prevalence-2018 - 2030
  • Fig. 171 Key country dynamics
  • Fig. 172 UAE cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 173 Cancer prevalence 2018 - 2030
  • Fig. 174 Key country dynamics
  • Fig. 175 Kuwait cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 176 Target disease prevalence
  • Fig. 177 Key payers in Kuwait
  • Fig. 178 Rest of MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 179 Key company categorization
  • Fig. 180 Company market share analysis, 2024
  • Fig. 181 Strategic framework
  • Fig. 182 Competitive heat map analysis for U.S.
  • Fig. 183 Competitive heat map analysis for UK